Neonc Technologies (NTHI) Projected to Post Earnings on Friday

Neonc Technologies (NASDAQ:NTHI) will likely be releasing its results before the market opens on Friday, March 20th. Analysts expect Neonc Technologies to post earnings of ($0.37) per share for the quarter.

Neonc Technologies Stock Up 3.2%

NASDAQ:NTHI traded up $0.28 during mid-day trading on Monday, reaching $8.93. The company’s stock had a trading volume of 51,488 shares, compared to its average volume of 56,781. The company’s fifty day simple moving average is $9.44 and its two-hundred day simple moving average is $9.39. Neonc Technologies has a twelve month low of $3.20 and a twelve month high of $25.00.

Institutional Trading of Neonc Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of the business. 683 Capital Management LLC acquired a new stake in Neonc Technologies during the 4th quarter worth approximately $442,000. OMERS ADMINISTRATION Corp acquired a new position in Neonc Technologies during the fourth quarter valued at approximately $126,000. Barclays PLC grew its stake in Neonc Technologies by 5,314.8% during the fourth quarter. Barclays PLC now owns 9,151 shares of the company’s stock worth $76,000 after buying an additional 8,982 shares during the period. State Street Corp grew its stake in Neonc Technologies by 9.9% during the fourth quarter. State Street Corp now owns 43,170 shares of the company’s stock worth $357,000 after buying an additional 3,900 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Neonc Technologies in the fourth quarter worth $124,000.

Analyst Ratings Changes

Several research analysts have recently weighed in on NTHI shares. Zacks Research upgraded shares of Neonc Technologies to a “hold” rating in a report on Wednesday, January 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Neonc Technologies in a report on Monday, December 29th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Neonc Technologies has a consensus rating of “Reduce”.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.